Palumbo Wealth Management LLC Acquires Shares of 12,140 Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Palumbo Wealth Management LLC bought a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 12,140 shares of the company’s stock, valued at approximately $26,000.

A number of other institutional investors have also made changes to their positions in the business. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Ventyx Biosciences by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after buying an additional 5,310 shares during the period. SG Americas Securities LLC acquired a new position in shares of Ventyx Biosciences during the 2nd quarter worth approximately $32,000. The Manufacturers Life Insurance Company increased its holdings in shares of Ventyx Biosciences by 41.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Ventyx Biosciences in the second quarter valued at approximately $58,000. Finally, Norden Group LLC acquired a new position in Ventyx Biosciences in the 1st quarter valued at $59,000. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Price Performance

VTYX stock traded down $0.04 during trading on Thursday, reaching $2.17. 81,628 shares of the company were exchanged, compared to its average volume of 2,087,926. Ventyx Biosciences, Inc. has a twelve month low of $1.79 and a twelve month high of $15.81. The company has a market capitalization of $153.35 million, a price-to-earnings ratio of -0.79 and a beta of 0.36. The company has a 50-day moving average of $2.25 and a two-hundred day moving average of $2.94.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.12. On average, analysts forecast that Ventyx Biosciences, Inc. will post -2.14 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on VTYX shares. HC Wainwright restated a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research report on Tuesday, October 15th. Wells Fargo & Company dropped their target price on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Finally, Canaccord Genuity Group reduced their price target on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.29.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.